Lancet 371:1505–1512PubMedCrossRef 34. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Center JR, Nguyen TV, Bagger Y, Gulcher JR, Eisman JA, PF-04929113 research buy Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K (2008) Multiple genetic loci for bone mineral density and fractures. N Engl J Med 358:2355–2365PubMedCrossRef 35. Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Snorradottir S,

Center JR, Nguyen TV, Alexandersen P, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K (2009) New sequence variants associated with bone mineral

density. Nat Genet 41:15–17PubMedCrossRef MK-4827 order 36. Abecasis GR, Cookson WO, Cardon LR (2001) The power to detect linkage disequilibrium with quantitative traits in selected samples. Am J Hum Genet 68:1463–1474PubMedCrossRef 37. Purcell S, Cherny SS, Sham PC (2003) Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19:149–150PubMedCrossRef”
“Introduction Minodronate is a nitrogen-containing bisphosphonate with a potent inhibitory effect on bone resorption. In a head-to-head comparison of the effects of minodronate with alendronate in postmenopausal osteoporosis patients, daily 1 mg minodronate resulted in similar increases in lumbar spine (LS) and total hip bone mineral density (BMD) after 12 months with similar safety profiles

[1]. A randomized placebo-controlled trial conducted in Japan revealed that daily 1 mg minodronate reduced vertebral fractures by 59% in postmenopausal women with established ever osteoporosis [2]. Daily 1 mg minodronate has been approved to treat involutional osteoporosis in Japan. Most oral bisphosphonates originally developed as a daily regimen have been shown to have equivalent efficacy with weekly and/or monthly regimens [3–7]. Since less frequent dosing, preferred by most patients, could result in LY2874455 concentration better treatment compliance with better outcomes [8], we conducted a study to determine if minodronate could be administered as a monthly regimen. The present randomized, double-blind, active-controlled 1-year study was undertaken to determine whether or not once monthly oral minodronate at doses of 30 and 50 mg provides similar efficacy and safety as the 1-mg daily regimen in patients with involutional osteoporosis.